This shows you the differences between two versions of the page.
Both sides previous revision Previous revision Next revision | Previous revision Next revision Both sides next revision | ||
home:publications [19.11.2019 10:32] Juha Kekäläinen |
home:publications [27.01.2020 16:29] Juha Kekäläinen |
||
---|---|---|---|
Line 6: | Line 6: | ||
### 2019 | ### 2019 | ||
- | Karttunen, J.; Heiskanen, M.; Lipponen, A.; Poulsen, D.; Pitkänen, | + | Das Gupta, S., Lipponen, A., Paldanius, K.M.A. et al. **Dynamics of clusterin protein expression in the brain and plasma following experimental traumatic brain injury.** Sci Rep 9, 20208 (2019), https:// |
- | Failli M, Paananen | + | Ngo Trong T, Mehtonen |
- | Timonen O, Särkkä M, Fülöp T, Mattsson A, Kekäläinen J, Paananen | + | Paananen, J; Fortino, V. **An omics perspective on drug target discovery platforms.**, //Brief Bioinform.// |
- | Lipponen | + | Nikkilä |
- | Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, Mäkinen | + | Sallinen H, Janhonen S, Pölönen P, Niskanen H, Liu OH, Kivelä |
- | Mehtonen J, Pölönen P, Häyrynen S, Lin J, Liuksiala T, Granberg K, Lohi O, Hautamäki V, Nykter M, Heinäniemi M. **Data-driven characterization of molecular phenotypes across heterogenous sample collections**, | + | Lipponen A, Natunen T, Hujo M, Ciszek R, Hämäläinen E, Tohka J, Hiltunen M, Paananen J, Poulsen D, Kansanen E, Ndode-Ekane XE, Levonen AL, Pitkänen A. **In Vitro and In Vivo Pipeline for Validation of Disease-Modifying Effects of Systems Biology-Derived Network Treatments for Traumatic Brain Injury—Lessons Learned**, //Int. J. Mol. Sci.// 2019 Oct, https:// |
- | //Nucleic Acids Research// 2019, https:// | + | |
+ | Pölönen P, Jawahar Deen A, Leinonen HM, Jyrkkänen HK, Kuosmanen S, Mononen M, Jain A, Tuomainen T, Pasonen-Seppänen S, Hartikainen JM, Mannermaa A, Nykter M, Tavi P, Johansen T, Heinäniemi M, Levonen AL. **Nrf2 and SQSTM1/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma.**, | ||
+ | |||
+ | Benhammou JN, Ko A, Alvarez M, Kaikkonen MU, Rankin C, Garske KM, Padua D, Bhagat Y, Kaminska D, Kärjä V, Pihlajamäki J, Pisegna JR, Pajukanta P. **Novel Lipid Long Intervening Noncoding RNA, Oligodendrocyte Maturation-Associated Long Intergenic Noncoding RNA, Regulates the Liver Steatosis Gene Stearoyl-Coenzyme A Desaturase As an Enhancer RNA.**, //Hepatol Commun.// 2019 Aug, https:// | ||
+ | |||
+ | Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA. **Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.**, | ||
+ | |||
+ | Failli M, Paananen J, Fortino V. **Prioritizing target-disease associations with novel safety and efficacy scoring methods**, //Sci Rep// 2019 Jul, https:// | ||
+ | |||
+ | Pölönen P, Mehtonen J, Lin J, Liuksiala T, Häyrynen S, Teppo S, Mäkinen A, Kumar A, Malani D, Pohjolainen V, Porkka K, Heckman CA, May P, Hautamäki V, Granberg K, Lohi O, Nykter M, Heinäniemi M. **Hemap: An interactive online resource for characterizing molecular phenotypes across hematologic malignancies**, | ||
+ | |||
+ | Mehtonen J, Pölönen P, Häyrynen S, Lin J, Liuksiala T, Granberg K, Lohi O, Hautamäki V, Nykter M, Heinäniemi M. **Data-driven characterization of molecular phenotypes across heterogenous sample collections**, | ||
+ | |||
+ | Marttinen M, Paananen J, Neme A, Mitra V, Takalo M, Natunen T, Paldanius KMA, Mäkinen P, Bremang M, Kurki MI, Rauramaa T, Leinonen V, Soininen H, Haapasalo A, Pike I, Hiltunen M **A multiomic approach to characterize the temporal sequence in Alzheimer' | ||
+ | |||
+ | Jauhiainen S, Laakkonen JP, Ketola K, Toivanen PI, Nieminen T, Ninchoji T, Levonen AL, Kaikkonen MU, Ylä-Herttuala S. **Axon Guidance-Related Factor FLRT3 Regulates VEGF-Signaling and Endothelial Cell Function.**, | ||
+ | |||
+ | Viiri LE, Rantapero T, Kiamehr M, Alexanova A, Oittinen M, Viiri K, Niskanen H, Nykter M, Kaikkonen MU, Aalto-Setälä K. **Extensive reprogramming of the nascent transcriptome during iPSC to hepatocyte differentiation.**, | ||
+ | |||
+ | Karttunen, J.; Heiskanen, M.; Lipponen, A.; Poulsen, D.; Pitkänen, A. **Extracellular Vesicles as Diagnostics and Therapeutics for Structural Epilepsies**, | ||
+ | |||
+ | Gurzeler E, Aavik E, Laine A, Valkama T, Niskanen H, Huusko J, Kaikkonen MU, Ylä-Herttuala S. **Therapeutic effects of rosuvastatin in hypercholesterolemic prediabetic mice in the absence of low density lipoprotein receptor.**, | ||
+ | |||
+ | Timonen O, Särkkä M, Fülöp T, Mattsson A, Kekäläinen J, Paananen J. **Varanto: variant enrichment analysis and annotation**, | ||
Line 28: | Line 51: | ||
Lewis, JD, Evans, AC, Tohka J. **T1 white/gray contrast as a predictor of chronological age, and an index of cognitive performance** // | Lewis, JD, Evans, AC, Tohka J. **T1 white/gray contrast as a predictor of chronological age, and an index of cognitive performance** // | ||
- | |||
- | Marttinen M, Paananen J, Neme A, Mitra V, Takalo M, Natunen T, | ||
- | Paldanius KMA, Mäkinen P, Bremang M, Kurki MI, Rauramaa T, Leinonen V, | ||
- | Soininen H, Haapasalo A, Pike I, Hiltunen M **A multiomic approach to characterize the temporal sequence in Alzheimer' | ||
Martiskainen H, Takalo M, Solomon A, Stančáková A, Marttinen M, | Martiskainen H, Takalo M, Solomon A, Stančáková A, Marttinen M, | ||
Line 43: | Line 62: | ||
### 2017 or earlier | ### 2017 or earlier | ||
- | - to be listed here later... | + | Paananen, J. **Bioinformatics in the Identification of Novel Targets and Pathways in Neurodegenerative Diseases**, Curr Genet Med Rep (2017) 5:15–21, https://doi.org/10.1007/ |